Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME
31 oct. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Data presented at the 12th...
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
19 oct. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it has completed its technology transfer of the Ampligen®...
Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
29 août 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it will present at CHI’s 4th Annual Immuno-Oncology...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
23 août 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 23, 2016 (GLOBE...
Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®
27 juil. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...
Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe
25 juil. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 25, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe...
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
07 juin 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 07, 2016 (GLOBE NEWSWIRE) -- Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology,...
Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)
10 mars 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
28 sept. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
23 sept. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...